Challenges and Opportunities in Gene Delivery - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 72

Acknowledgment
The authors acknowledge the financial assistance from the Council of Scientific
and Industrial Research (CSIR), New Delhi, India and TIFAC CORE in NDDS,
Government of India, New Delhi for providing the research facilities to the team.
References
[1] Verma IM, Somia N. Gene therapy promises, problems and prospects. Nature 1997;
389:239-42.
[2] Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene
therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med
2009;360:447-58.
[3] Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Brenda M, et al.
Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in
liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009;119:2086-99.
[4] Shichiri M, Tanaka A, Hirata Y. Intravenous gene therapy for familial hypercholesterol-
emia using ligand-facilitated transfer of a liposome: LDL receptor gene complex. Gene
Ther 2003;10:827-31.
[5] Griesenbach U, Alton E. Cystic fibrosis gene therapy: successes, failures and hopes for
the future. Expert Rev Respir Med 2009;3:363-71.
[6] Arumugam P, Urbinati F, Higashimoto T, Perumbeti A, Malik P. Lentivirus vectors for
gene therapy for hemoglobinopathies. Blood Cells Mol Dis 2008;40:275-6.
[7] Brady RO, Barton NW. Enzyme replacement and gene therapy for Gaucher's disease.
Lipids 1996;31:S137-9.
[8] Zhang D, Wu M, Nelson DE, Pasula R, Martin WJ. Alpha-1-antitrypsin expression in
the lung is increased by airway delivery of gene-transfected macrophages. Gene Ther
2003;10:2148-52.
[9] Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet 2002;11:
2355-62.
[10] Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF, et al. Systemic p 53
gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Mol Med 2001;7:723-34.
[11] Palfi S. Toward gene therapy for Parkinson's disease. Lancet Neurol 2008;7:375-76.
[12] Federoff HJ. Alzheimer's disease: reducing the burden with ApoE2. Gene Ther
2005;12:1019-29.
[13] Koransky ML, Robbins RC, Blau HM. VEGF gene delivery for treatment of ischemic
cardiovascular disease. Trends Cardiovasc Med 2002;12:108-14.
[14] Bunnell BA, Morgan RA. Gene therapy for infectious diseases. Clin Microbiol Rev
1998;11:42-56.
[15] Ledley FD. Non-viral gene therapy. Curr Opin Biotechnol 1994;5:626-36.
[16] Ledley FD. Development in somatic gene therapy. Expert Opin Invest Drugs 1994;3:
913-21.
[17] Anderson WF. Human gene therapy. Science 1992;256:808-13.
[18] Tomlinson E, Rolland AP. Controllable gene therapy pharmaceutics of non-viral gene
delivery systems. J Control Release 1996;39:357-72.